Daily statin reduces risk of cardiovascular disease in people living with HIV, UC study finds
Results could produce a change in practice guidelines
An international multicenter study that was conducted at the University of Cincinnati was stopped early after research demonstrated that a daily statin medication reduced the risk of cardiovascular disease among people living with HIV.
A planned interim analysis of data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found that participants who took pitavastatin calcium lowered their risk of major adverse cardiovascular events by 35% compared with those receiving a placebo.
REPRIEVE is the first large-scale clinical study to test a primary cardiovascular prevention strategy for people living with HIV.
Adverse drug events observed in the study were comparable to those in the general population taking statin therapy. The interim analysis was sufficiently compelling that the study’s independent Data Safety and Monitoring Board (DSMB) recommended it be stopped early given adequate evidence of efficacy. The National Institutes of Health accepted the DSMB recommendations.
Study participants are being notified of the findings and will continue to be monitored for several months. Study results from the DSMB review are expected to be published in the coming weeks.
REPRIEVE, launched in 2015, enrolled 7,769 volunteers between 40 to 75 years of age, of whom more than 30% were women. All REPRIEVE volunteers took antiretroviral therapy and had low-to-moderate traditional cardiovascular disease risk that would not typically be considered for statin treatment.
The trial was conducted in 12 countries in Asia, Europe, North America, South America and Africa. UC enrolled 112 participants in the main study and 55 participants in the mechanistic substudy. Carl Fichtenbaum, MD, professor of Infectious Diseases at the UC College of Medicine, was the vice-chair of the REPRIEVE protocol serving on the core team that ran the study.
The REPRIEVE study is primarily supported by the National Institute of Allergy and Infectious Diseases and the National Heart, Lung and Blood Institute with additional funding from the NIH Office of AIDS Research. The study was conducted by the AIDS Clinical Trials Group (ACTG).
“It is incredibly gratifying to see these results and to know that this study has the potential to change clinical practice and thus have a meaningful impact on the experiences and health of people living with HIV,” said Fichtenbaum.
“This area of research has been a priority of the ACTG for 20 years and I want to congratulate the many individuals within the network and dedicated study participants who have contributed to making REPRIEVE such a success.”
Statins are known to prevent cardiovascular disease among those at high risk in the general population and REPRIEVE sought to understand whether they would have the same effect among people living with HIV who may not traditionally be candidates for statins.
It was not clear if statins would have the same effect in people living with HIV and who have premature cardiovascular disease despite having low-to-moderate traditional risk. In the REPRIEVE trial, participants were randomly assigned to receive a daily dose of 4 mg of pitavastatin or placebo. They were monitored for major adverse cardiovascular events and adverse reactions to pitavastatin, which is considered safe for use with all prescribed antiretroviral therapy regimens.
Featured image at top of an HIV cell: National Institutes of Health
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Bono, Chris Tucker Visit UC To Discuss Africa
December 5, 2002
U2's Bono and comedian-actor Chris Tucker led a delegation from the DATA organization who came to UC to talk about potentially catastrophic problems in Africa.
New Year's Help for Those Looking to Kick the Habit
December 20, 2002
Quitting smoking consistently ranks among the top three resolutions made by New Year's resolvers each year.
E-BRIEF: Let's Toast to a Healthier 2003
January 8, 2003
The New Year often means a new health kick: Vows to tone up and trim down, and maybe going to the doctor and getting ourselves as regularly "maintenanced" as we do our cars. So, this week's University of Cincinnati e-briefing examines the health concerns of the young and old, and what you should be doing to preserve your good health.
Today's ML King Events: One On, One Off
January 8, 2003
A memorial march, presentations, poetry and dance will pay tribute to the slain civil rights leader.
UC Named Lead Organization for OSHA Training Consortium
January 13, 2003
UC Continuing Medical Education (CME) has been selected as the lead organization for the Occupational Safety and Health Administration (OSHA) Great Lakes Training Consortium by the U.S. Department of Labor.
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 13, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 14, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 20, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 21, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
Leader of Fetal Surgery to Deliver Lectures at UC
January 31, 2003
An internationally recognized authority on fetal surgery will lecture at the UC Medical Center, representing the first of a series of lectures on fetal surgery presented by the department of Obstetrics and Gynecology (Ob/Gyn).